



Guía de instrucciones: AIDS 2020 Knowledge Toolkits

Esta guía de instrucciones ofrece una descripción general de cómo navegar por el conjunto de herramientas de conocimiento de la AIDS 2020. Desarrollado por IAS – la International AIDS Society, estas herramientas forman parte de un objetivo principal de la organización de invertir en la fuerza laboral del VIH para desarrollar las habilidades y los conocimientos que ayudarán a poner fin a la epidemia.


El paquete completo ofrece 18 conjuntos de herramientas descargables que fueron creados exclusivamente para que los miembros de la IAS puedan acceder a los últimos avances de la ciencia e investigación presentados en la 23a Conferencia Internacional sobre el sida (*AIDS 2020: Virtual*). Las herramientas también tienen como objetivo de asegurar que nuestros miembros puedan utilizar la información clave presentada a la conferencia más fácilmente y de mejor manera.

QUÉ ESTÁ INCLUIDO

Haga clic en el enlace del bloque científico en la página web para descargar automáticamente cada conjunto de herramientas por tema. Cada conjunto incluye la presentación de PowerPoint para esa pista incluido las notas de los ponentes correspondientes.


NAVEGACIÓN

Una vez descargadas, las presentaciones se han diseñado para permitir una navegación rápida a través de temas específicos, estudios, poblaciones y más.





La diapositiva "Resumen" (diapositiva tres en todos los conjuntos) incluye teclas que enlazan con temas específicos dentro de la presentación. Tenga en cuenta que todas las funciones deben realizarse desde el "modo presentación". Para volver a la diapositiva "Resumen", haga clic en el logotipo de la IAS en la esquina superior izquierda de cualquier diapositiva. Vea el ejemplo abajo.



IAS Acción prolongada
Oportunidades y desafíos en el campo de la acción prolongada

The challenge: Need to accelerate pipeline for application to pediatric medicines

LONGER-TERM (7 yrs)	MEDIUM-TERM (3 – 6 yrs)	NEAR-TERM (1 – 2 yrs)
Respirable film nebulizers	Oral films	Dispersible tablets (DTs)
Microencapsules	Long-acting oral products	Oral-dispersible tablets (ODTs)
Long-acting implants*	Long-acting implants*	Multi-particulate (MPs)
9 D Printing	9 D Printing	Mucoadhesive (1-2 mins)
		Long-acting depot nebulizers*
		Suppositories
		Transdermal technologies
		Enhanced bioavailability

The challenge: economic considerations for long-acting technologies expanded access in LMICs

Cost case

- Is the product affordable compared to existing care?
- If more expensive, how much more expensive?
- What are the risk and benefits as a relative to price compared to existing care?
- Is there evidence impact on work or income related to less visits to the health system and increased efficiencies?

Health Care Provider

- Depending on product administration requirements, are there barriers to full insurance or additional costs?
- Are there additional supplies or auxiliary costs that are required to use and dispense the product (e.g. pumps)?
- Will the product and care be covered by insurance?

Deployment

- What proportion of the population would need to access the long-acting tool?
- Is this a replacement product or new tool in health system?
- Given the price of the product per unit, would there be deficits in the existing procurement budget?
- Long term implications for budget?

Investment case

- Is the product affordable in the response in LMICs?
- If the product purchasing cost is expected to be higher than current standard of care, are there cost savings to the health systems?
- What is the return on investment?
- For treatment: increased population with viral suppression → decreased partner transmission & decreased risk of resistance?
- For prevention → decreased number of infections?
- How does the product contribute to meeting targets?

Unitaid World Origin

Carmen Perez Casas

REFERENCIAS Y FUENTES

Las referencias que fueron dadas en presentaciones claves de la conferencia están proporcionadas en la esquina inferior derecha de cada diapositiva (estos enlaces son de resúmenes abstractos, diapositivas de presentación o grabaciones de video, por ejemplo). Vea el ejemplo abajo.

IAS Acción prolongada
Oportunidades y desafíos en el campo de la acción prolongada

The challenge: Need to accelerate pipeline for application to pediatric medicines

LONGER-TERM (7 yrs+)	MEDIUM-TERM (3 – 6 yrs)	NEAR-TERM (1 – 2 yrs)
Needle free syringes	Oral films	Orally-dispersible tablets (ODTs)
Microneedles	Long-acting oral products	Orally-dispersible tablets (ODTs)
	Long-acting implants *	Multi-particulates (MNs)
	3-D Printing	Mucoadhesives (1-2 yrs)
		Long-acting depot syringes *
		Sublinguals
		Hotter-molding technologies
		Enhanced bioavailability

The challenge: economic considerations for long-acting technologies expanded access in LMICs

End-user

- Is the product affordable compared to existing care?
- If more expensive, how much more expensive?
- What are the risks and benefits as it relates to price compared to existing care?
- Is there positive impact on work or income related to less visits to the health system and increased effectiveness?

Health Care Provider

- Depending on product administration requirements, are there savings to HR resources or additional costs?
- Are there additional supplies or ancillary costs that are required to use (and dispose) the product (e.g., syringes)?
- Will the product and can be covered by insurance?

Deployment

- What proportion of the population would need to access the long-acting tool?
- Is this a replacement product or new tool in health system?
- Given the price of the product per unit, would there be deficits to the existing procurement budget?
- Long term implications for budget?

Investment case

- Is the product affordable in the response in LMICs?
- If the product purchasing cost is expected to be higher than current standard of care, are there **cost savings** to the health system?
- What is the return on investment?
- For treatment: increased population with viral suppression → decreased partner transmission & decreased risk of resistance?
- For prevention → decreased number of infections?
- How does the product contribute to meeting targets?

no data for age appropriateness
 Available products in LMICs
 Long-acting products
 Pipeline contains only applications for older ages.

Unitaid World Opioid

Carmen Perez Casas

CONTACTO

Comuníquese con el equipo de servicios para miembros de la IAS con cualquier pregunta o comentario, a memberservice@iasociety.org.